Two Phase 3 Trials of Baricitinib for Alopecia Areata
N Engl J Med. 2022. Epub ahead of print doi: 10.1056/NEJMoa2110343
Phase 3 trials in patients with severe alopecia areata show that baricitinib is superior to placebo with respect to hair regrowth at 36 weeks.
Alopecia areata is characterised by nonscarring hair loss that can affect any hair-bearing site. Although mild cases of this emotionally- and psychosocially-distressing autoimmune disease may resolve within 12 months, more severe forms of the disease are unlikely to remit without treatment.
Due to the involvement of cytokines in the pathogenesis of alopecia areata, previous reports have indicated that JAKinibs may reverse hair loss in these patients.
King, et al. implemented two Phase 3 randomised trials of baricitinib for alopecia areata, BRAVE-AA1 and BRAVE-AA2, with promising results at 36 weeks.
Keywords:
